¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"linear inhibition"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • linear scan
    ¼±½ºÄµ
  • linear scleroderma
    ¼±ÇǺΰæÈ­Áõ
  • linear sequenced array
    ¼±Çü¼øÂ÷¹è¿­, ÁÙ¸ð¾ç¼ø¼­¹è¿­
  • linear shadow
    ¼±À½¿µ
  • linear switched array
    ¼±Çü±³´ë½Ä¹è¿­, ÁÙ±³´ë½Ä¹è¿­
  • linear transducer
    ¼±ÇüŽÃËÀÚ
  • linear type constitution
    ¼±ÇüüÇü
  • verrucous linear nevus
    »ç¸¶±Í¸ð¾ç¼±¸ð¹Ý
  • antidromic inhibition
    ¿ª¹æÇâ¾ïÁ¦
  • afferent inhibition
    µé½Å°æ¾ïÁ¦, ±¸½É¾ïÁ¦
  • agar gel precipitin inhibition test
    ¿ì¹«°Öħ°­¼Ò¾ïÁ¦°Ë»ç
  • allogenic inhibition
    µ¿Á¾ÀÌÇü¾ïÁ¦
  • competitive inhibition
    °æÀï¾ïÁ¦
  • complement fixation inhibition test
    º¸Ã¼°áÇÕ¾ïÁ¦°Ë»ç
  • contact inhibition
    Á¢Ã˾ïÁ¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • linear
    ÁÙ¸ð¾ç-, ¼±Çü-, ¼±»ó-
  • linear molecule
    ¼±ÇüºÐÀÚ
  • linear nevus
    ¼±¸ð¹Ý
  • linear perspective
    ¼±»óÅõ½Ã
  • linear regression
    ¼±Çüȸ±Í
  • linear scale
    ±Õµî´«±Ý
  • linear scan
    ¼±½ºÄµ
  • linear scar
    ¼±ÈäÅÍ
  • linear scleroderma
    ¼±»óÇǺΰæÈ­Áõ
  • linear shadow
    ¼±±×¸²ÀÚ
  • linear tomography
    Á÷¼±½Ä´ÜÃþÃÔ¿µ¼ú
  • linear transducer
    ¼±ÇüŽÃËÀÚ
  • linear electronic scanner
    ¼±ÀüÀڽĽºÄ³³Ê
  • linear energy transfer radiation
    ¼±»ó¿¡³ÊÁöÀüȯ
  • linear quadratic model
    ¼±Çü¹æÇü¸ðµ¨, ¼±ÇüÀÌÂ÷ÇÔ¼ö¸ðµ¨
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • group Ia inhibition
    ¥°a¤ÇϹA.
  • group Ia inhibition
    ¥°a±º¾ïÁ¦(ÏØàéë«).
  • hemagglutination inhibition antibody
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦Ç×ü.
  • hemagglutination inhibition antibody
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦Ç×ü.
  • hemagglutination inhibition reaction
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦¹ÝÀÀ.
  • hemagglutination inhibition test
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè
  • hemagglutination inhibition test
    Ç÷±¸ÀÀÁý ÀúÁö½ÃÇè
  • hemagglutination inhibition test =HIT
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè.
  • hemagglutination-inhibition (HI) test
    Ç÷±¸ÀÀÁý ÀúÁö½ÃÇè
  • immunologic inhibition
    ¸é¿ªÇÐÀû ¾ïÁ¦.
  • indirect inhibition
    °£Á¢¾ïÁ¦.
  • inhibition
    ¾ïÁ¦,±ÝÁö
  • inhibition
    ¾ïÁ¦
  • inhibition
    ¾ïÁ¦, ÀúÁö
  • inhibition
    ¾ïÁ¦
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • linear array type
    ¼±Çü ¹è¿­½Ä (àÊû¡ ÛÕÖªãÒ)
  • linear arrays
    ¼±Çü ¹è¿­ (àÊû¡ ÛÕÖª)
  • linear attenuation coefficient
    ¼±Çü°¨¾à°è¼ö
  • linear calcification
    ¼±»ó¼®È¸È­(àÊßÒà´üéûù).
  • linear coefficient of expansion
    ¼±ÆØÃ¢°è¼ö(àÊø³óìÌõâ¦).
  • linear correlation
    ¼±»ó»ó°ü.
  • linear craniectomy
    Á÷¼±¼º<Á÷¼±»ó> µÎ°³±¹ºÎÀýÁ¦.
  • linear craniotomy
    Á÷¼±Àû¼âµÎ¼ú.
  • linear density
    ¼±»óÀ½¿µ
  • linear discriminant analysis
    ¼±»óÆÇº°ºÐ¼®
  • linear eccrine naevi with comedones => porokeratotic eccrine ostial an
  • linear electronic scanner
    ¼±Çü ÀüÀÚ½Ä ÃÊÀ½ÆÄ±â±â (àÊû¡ ï³í­ãÒ õ±ëå÷îÐïѦ)
  • linear electronic scanner
    ¼±Çü ÀüÀÚ½Ä ½ºÄ³³Ê
  • linear energy transfer
    ¼±»ó¿¡³ÊÁö Àü´Þ(àÊßÒ¡­ îîÓ¹)
  • linear energy transfer coefficient
    ¼±Çü¿¡³ÊÁöÀüÀ̰è¼ö
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • afferent inhibition
    ±¸½É¼ºÀúÇØ(Ï´ãýàõîÁúª)
  • anticompetitive inhibition
    Ç×°æÇÕ ÀúÇØ(ù÷ÌæùêîÁúª)
  • competitive inhibition
    °æÇÕÀúÇØ(ÌæùêîÁúª)
  • complement fixation inhibition test
    º¸Ã¼°íÁ¤ ÀúÇØ½ÃÇè(ÜÍô÷ͳïÒîÁúªãËúÐ)
  • concerted divalent inhibition
    Çùµ¿ À̰¡ ÀúÇØ(úðÔÒì£Ê¤îÁúª)
  • concerted feedback inhibition
    Çùµ¿(úðÔÒ) µÇ¸ÔÀÓ ÀúÇØ(îÁúª)
  • contact inhibition
    Á¢ÃËÀúÇØ(ïÈõºîÁúª)
  • cooperative feedback inhibition
    Çùµ¿(úðÔÒ) µÇ¸ÔÀÓÀúÇØ(îÁúª)
  • coupling inhibition
    "¦Áþ±â ÀúÇØ(îÁúª), (ÔÒ) uncompetitive inhibition"
  • cumulative feedback inhibition
    ´©Àû(׫îÝ) µÇ¸ÔÀÓ ÀúÇØ(îÁúª)
  • density inhibition
    "¹ÐµµÀúÇØ(ÚËÓøîÁúª), (ÔÒ) contact inhibition"
  • end-product inhibition
    Á¾»ê¹° ÀúÇØ (ðûß§ÚªîÁúª)
  • enzyme multiplicity feedback inhibition
    È¿¼Ò ´Ù¾ç¼º(ý£áÈÒýåÆàõ) µÇ¸ÔÀÓ ÀúÇØ(îÁúª)
  • feedback inhibition
    µÇ¸ÔÀÓ ÀúÇØ(îÁúª)
  • hapten inhibition test
    ÇÕÅÙ ÀúÇØ½ÃÇè(ãËúÐ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • linear scan motion
    ¼±Çü½ºÄµ¿îµ¿
  • linear sequenced array
    ¼±Çü¿¬¼â¹è¿­
  • linear shadow
    ¼±»óÀ½¿µ
  • linear streak
    ¼±»ó¼±
  • linear switched array
    ¼±Çü±³´ë½Ä¹è¿­
  • linear transducer
    ¼±Çü ŽÃËÀÚ
  • linear transducer array
    ¼±»óÆ®·£½ºµà¼­¹è¿­
  • linear ulcer
    ¼±»ó±Ë¾ç
  • peripheral linear enhancement
    ¸»Ãʼ±ÇüÁ¶¿µÁõ°­
  • phased linear array type
    À§»óÂ÷¼±Çü¹è¿­½Ä
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
DLP delipidized serum protein; direct linear plotting; dislocation of patella; distolinguopulpal; dyshar...
GLIM generalized linear interactive model
GLM general linear model
LAS laboratory automation system; lateral amyotrophic sclerosis; laxative abuse syndrome; left anterior-...
LASA linear-analogue self assessment
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LET High-linear energy transfer
ILVEN Inflammatory Linear Verrucous Epidermal Nevus
LINAC Linear Accelerator
LAS Linear Alkylbenzene Sulphonate
LASA Linear Analogue Self Assessment
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • allogeneic inhibition
    µ¿Á¾ ÀÌÇü ¾ïÁ¦
  • antagonistic inhibition
    ±æÇ×±Ù ¾ïÁ¦, ±æÇ×Àû ¾ïÁ¦, ±æÇ×Àû ÀúÇØ
  • antidromic inhibition
    ¿ª¹æÇ⼺ ¾ïÁ¦
  • competitive inhibition
    °æÀïÀû ¾ïÁ¦, °æÇÕ¼º ¾ïÁ¦
    ¾î¶² ¼ö¿ëü¿¡ ´ëÇØ °áÇÕ·ÂÀÌ Å« ¹°ÁúÀÌ »ó´ëÀûÀ¸·Î °áÇÕ·ÂÀÌ ¾àÇÑ ´Ù¸¥ ¹°ÁúÀÇ °áÇÕÀ» ¾ïÁ¦ÇÏ´Â °Í.
  • complement fixation inhibition test
    º¸Ã¼ °íÁ¤ ÀúÇØ ½ÃÇè
  • cyto- ¼¼Æ÷¿ÍÀÇ °ü°è¸¦ ³ªÅ¸³»´Â Á¢µÎ¾î.

    cyto-inhibition

    ¼¼Æ÷ ¾ïÁ¦ ÀÛ¿ë
    ޽ÄÇÑ ¼¼±Õ ¶Ç´Â ¹ÙÀÌ·¯½º¸¦ ¿ëÇØÇϰųª È­Çпä¹ýÁ¦¿¡ ÀÇÇÑ È­ÇÐÀû ÆÄ±«·ÎºÎÅÍ ¹æ¾îÇÏ´Â ½Ä ¼¼Æ÷ÀÇ ÀÛ¿ë.
  • enzyme inhibition
    È¿¼Ò ¾ïÁ¦
  • factor macrophage migration inhibition
    ´ë½Ä ¼¼Æ÷ À¯ÁÖ ÀúÁö ÀÎÀÚ
  • hapten inhibition test
    ÇÕÅÙ ÀúÇØ ½ÃÇè
    Ç×üÀÇ Ç׿ø Ư¼ö °áÇÕ ºÎÀ§¸¦ µ¤´Â ÇÕÅÙÀ» ÀÌ¿ëÇÏ¿© Ç׿ø °áÁ¤±âÀÇ Ç÷ûÇÐÀû Ư¼ºÀ» °Ë»çÇÏ´Â ½ÃÇè.
  • hemagglutination inhibition test
    ÀûÇ÷±¸ ÀÀÁý ¾ïÁ¦ ½ÃÇè
  • inhibition
    ¾ïÁ¦, ÀúÁö, ÀúÇØ
    °úÁ¤ÀÇ ¾ï¾Ð
  • inhibition reaction
    ¾ïÁ¦, ¾ïÁ¦ ¹ÝÀÀ, ÀúÁö, ÀúÁö ¹ÝÀÀ
  • inhibition zone
    ¾ïÁ¦´ë
    ħ°­ ¶Ç´Â ÀÀÁý ¹ÝÀÀ¿¡¼­ Ç×ü ³óµµ°¡ ³ôÀº Ç÷û¿¡¼­´Â Ç׿ø ÀÔÀÚ¿Í ¹ÝÀÀÀ» ³ªÅ¸³»Áö ¾Ê´Â Çö»ó.
  • lateral inhibition
    Ãø¹æ ¾ïÁ¦
    ÈïºÐÇϰí ÀÖ´Â ¿ä¼Ò¿¡ ÀÇÇÏ¿© ÀÎÁ¢ÇÏ´Â ¿ä¼ÒÀÇ È°µ¿ÀÌ ¾ïÁ¦µÇ´Â Çö»ó.
  • lingering inhibition

    lingissimus capitis (µÎÃÖÀå±Ù

    »óÃø 4¡­5 ÈäÃßÀÇ È¾µ¹±â¿Í ÇÏÃø 3¡­4 °æÃßÀÇ °üÀýµ¹±â¿¡¼­ ±â½ÃÇÏ¿© ÃøµÎ°ñÀÇ À¯¾çµ¹±â¿¡¼­ Á¤ÁöÇÑ´Ù. °æ ½Å°æ °¡ÁöÀÇ Áö¹è¸¦ ¹ÞÀ¸¸ç, ¸Ó¸®¸¦ ÈĹæÀ¸·Î ´ç±â°í ȸÀü½ÃŲ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
linear skull fracture A skull fracture resembling a line.
(05 Mar 2000)
allogeneic inhibition Inhibition or injury to allogeneic cells that occurs when lymphocytes are mixed and cultured with other cells of different genotypes in vitro.
(05 Mar 2000)
macrophage inhibition factor <cytokine> A group of lymphokines (including a 14 kD glycoprotein) produced by activated T lymphocytes that reduces macrophage mobility and probably increases macrophage macrophage adhesion.
(18 Nov 1997)
macrophage migration inhibition test A test which measures the presence of migration-inhibitory factor. Usually peritoneal macrophages are placed in a capillary tube in the presence or absence of supernatants from activated T-cells. If MIF is present, the migration of monocyte/macrophages is reduced.
Synonym: macrophage migration inhibition test, migration inhibition test.
(05 Mar 2000)
reactive inhibition Tendency toward a lessened strength of response due to practice or activity. It is independent of the effect of reward and is a direct function of time interval since the last response and the number of preceding responses.
(12 Dec 1998)
reciprocal inhibition Contraction in a muscle is accompanied by a loss of tone or by relaxation in the antagonistic muscle.
Synonym: reciprocal inhibition.
(05 Mar 2000)
reflex inhibition A situation in which sensory stimuli decrease reflex activity.
(05 Mar 2000)
cell migration inhibition Phenomenon of cell-mediated immunity measured by in vitro inhibition of the migration or phagocytosis of antigen-stimulated leukocytes or macrophages. Specific assays have been developed to estimate levels of migration-inhibitory factor, immune reactivity against tumour-associated antigens, and immunosuppressive effects of infectious microorganisms.
(12 Dec 1998)
central inhibition <physiology> Suppression or diminution of outgoing impulses from a reflex centre.
(05 Mar 2000)
residual inhibition The inhibition or suppression of tinnitus by use of a sound-generating device (residual inhibitor) which masks the sounds of tinnitus and produces a residual sound-inhibiting effect when the device is turned off.
(05 Mar 2000)
retroactive inhibition The partial or complete obliteration of memory by a more recent event, particularly new learning.
Compare: proactive inhibition.
(05 Mar 2000)
migration inhibition test A test which measures the presence of migration-inhibitory factor. Usually peritoneal macrophages are placed in a capillary tube in the presence or absence of supernatants from activated T-cells. If MIF is present, the migration of monocyte/macrophages is reduced.
Synonym: macrophage migration inhibition test, migration inhibition test.
(05 Mar 2000)
Wedensky inhibition Inhibition of muscle response resulting from application of a series of rapidly repeated stimuli to the motor nerve where slower frequency of stimulation results in muscle response.
(05 Mar 2000)
competitive inhibition <chemistry> Inhibitor that occupies the active site of an enzyme or the binding site of a receptor and prevents the normal substrate or ligand from binding.
at sufficiently high concentration of the normal ligand inhibition is lost: the Km is altered by the competitive inhibitor, but the Vmax remains the same.
(05 Jan 1998)
contact inhibition The inhibition of continued growth and division of a cell or colony due to physical contact with other cells or colonies. The stopping of continued growth when a certain density of cells has been reached.
The momentary stopping of all movement when a mobile cell runs into another cell.
(09 Oct 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á